TAOX

TAOX
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $3.962K ▲ | $3.04M ▲ | $-17.516M ▼ | -442.102K% ▼ | $-11.26 ▼ | $-2.335M ▼ |
| Q1-2025 | $0 | $1.069M ▼ | $385.169K ▲ | 0% | $0.12 ▲ | $-1.068M ▲ |
| Q4-2024 | $0 | $2.179M ▲ | $-5.547M ▲ | 0% | $-4.18 ▲ | $-2.177M ▼ |
| Q3-2024 | $0 | $1.36M ▼ | $-5.742M ▼ | 0% | $-4.58 ▼ | $-1.358M ▲ |
| Q2-2024 | $0 | $1.581M | $-1.273M | 0% | $-1.18 | $-1.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $14.37M ▼ | $19.792M ▲ | $1.827M ▼ | $17.964M ▲ |
| Q1-2025 | $14.833M ▼ | $15.329M ▼ | $8.882M ▼ | $6.448M ▼ |
| Q4-2024 | $17.656M ▼ | $17.734M ▼ | $10.957M ▲ | $6.777M ▼ |
| Q3-2024 | $22.069M ▼ | $22.826M ▼ | $9.71M ▲ | $13.116M ▼ |
| Q2-2024 | $27.414M | $28.385M | $9.589M | $18.797M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-17.516M ▼ | $-749.072K ▲ | $-4.5M ▼ | $4.786M ▲ | $-463.545K ▲ | $-749.072K ▲ |
| Q1-2025 | $385.169K ▲ | $-2.001M ▼ | $0 | $-822.362K ▼ | $-2.823M ▼ | $-2.001M ▼ |
| Q4-2024 | $-19.991M ▼ | $-1.168M ▼ | $0 | $-801.694K ▲ | $-1.97M ▲ | $-1.168M ▼ |
| Q3-2024 | $8.702M ▲ | $-1.031M ▼ | $0 ▲ | $-4.32M ▼ | $-5.351M ▼ | $-1.031M ▼ |
| Q2-2024 | $-1.273M | $-853.534K | $-500K | $0 | $-1.354M | $-853.534K |
Five-Year Company Overview
Income Statement

Balance Sheet

Cash Flow

Competitive Edge

Innovation and R&D

Summary
TAO Synergies is best viewed as an early-stage, highly specialized investment vehicle rather than a conventional healthcare or biotech operator. Financially, it is pre-revenue, runs a relatively lean cost base, and has historically had a small, debt-free balance sheet that is evolving into a concentrated crypto asset portfolio. Strategically, the company’s core bet is that decentralized AI and the Bittensor network will grow in importance and value, and that a regulated, public wrapper around TAO exposure will be attractive to investors. Its first-mover status, active staking, subnet investments, and media presence give it a differentiated position in a very narrow space. The opportunity is clear: meaningful upside if Bittensor adoption, TAO’s value, and staking economics develop favorably. The risks are equally clear: extreme dependence on one ecosystem, high token and regulatory volatility, and an income model that is not yet proven at scale. TAOX’s future performance will largely track the health, adoption, and market perception of Bittensor and the TAO token rather than traditional operating metrics.
NEWS
November 18, 2025 · 9:15 AM UTC
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
Read more
November 4, 2025 · 9:15 AM UTC
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
Read more
October 20, 2025 · 9:15 AM UTC
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
Read more
October 13, 2025 · 5:09 PM UTC
TAO Synergies Announces $11 Million Private Placement
Read more
September 22, 2025 · 9:15 AM UTC
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)
Read more
About TAO Synergies Inc.
https://www.synaptogen.comClinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $3.962K ▲ | $3.04M ▲ | $-17.516M ▼ | -442.102K% ▼ | $-11.26 ▼ | $-2.335M ▼ |
| Q1-2025 | $0 | $1.069M ▼ | $385.169K ▲ | 0% | $0.12 ▲ | $-1.068M ▲ |
| Q4-2024 | $0 | $2.179M ▲ | $-5.547M ▲ | 0% | $-4.18 ▲ | $-2.177M ▼ |
| Q3-2024 | $0 | $1.36M ▼ | $-5.742M ▼ | 0% | $-4.58 ▼ | $-1.358M ▲ |
| Q2-2024 | $0 | $1.581M | $-1.273M | 0% | $-1.18 | $-1.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $14.37M ▼ | $19.792M ▲ | $1.827M ▼ | $17.964M ▲ |
| Q1-2025 | $14.833M ▼ | $15.329M ▼ | $8.882M ▼ | $6.448M ▼ |
| Q4-2024 | $17.656M ▼ | $17.734M ▼ | $10.957M ▲ | $6.777M ▼ |
| Q3-2024 | $22.069M ▼ | $22.826M ▼ | $9.71M ▲ | $13.116M ▼ |
| Q2-2024 | $27.414M | $28.385M | $9.589M | $18.797M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-17.516M ▼ | $-749.072K ▲ | $-4.5M ▼ | $4.786M ▲ | $-463.545K ▲ | $-749.072K ▲ |
| Q1-2025 | $385.169K ▲ | $-2.001M ▼ | $0 | $-822.362K ▼ | $-2.823M ▼ | $-2.001M ▼ |
| Q4-2024 | $-19.991M ▼ | $-1.168M ▼ | $0 | $-801.694K ▲ | $-1.97M ▲ | $-1.168M ▼ |
| Q3-2024 | $8.702M ▲ | $-1.031M ▼ | $0 ▲ | $-4.32M ▼ | $-5.351M ▼ | $-1.031M ▼ |
| Q2-2024 | $-1.273M | $-853.534K | $-500K | $0 | $-1.354M | $-853.534K |
Five-Year Company Overview
Income Statement

Balance Sheet

Cash Flow

Competitive Edge

Innovation and R&D

Summary
TAO Synergies is best viewed as an early-stage, highly specialized investment vehicle rather than a conventional healthcare or biotech operator. Financially, it is pre-revenue, runs a relatively lean cost base, and has historically had a small, debt-free balance sheet that is evolving into a concentrated crypto asset portfolio. Strategically, the company’s core bet is that decentralized AI and the Bittensor network will grow in importance and value, and that a regulated, public wrapper around TAO exposure will be attractive to investors. Its first-mover status, active staking, subnet investments, and media presence give it a differentiated position in a very narrow space. The opportunity is clear: meaningful upside if Bittensor adoption, TAO’s value, and staking economics develop favorably. The risks are equally clear: extreme dependence on one ecosystem, high token and regulatory volatility, and an income model that is not yet proven at scale. TAOX’s future performance will largely track the health, adoption, and market perception of Bittensor and the TAO token rather than traditional operating metrics.
NEWS
November 18, 2025 · 9:15 AM UTC
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
Read more
November 4, 2025 · 9:15 AM UTC
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
Read more
October 20, 2025 · 9:15 AM UTC
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
Read more
October 13, 2025 · 5:09 PM UTC
TAO Synergies Announces $11 Million Private Placement
Read more
September 22, 2025 · 9:15 AM UTC
TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)
Read more

CEO
Joshua N. Silverman
Compensation Summary
(Year 2024)

CEO
Joshua N. Silverman
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : C-

